Honest GLP-1 Telehealth
Provider Reviews

GLP-1 receptor agonists are a class of medications that mimic the glucagon-like peptide-1 hormone your body naturally produces. They work by helping regulate appetite, slowing gastric emptying, and improving insulin sensitivity. The two most common active ingredients are semaglutide (found in brand names like Wegovy and Ozempic) and tirzepatide (found in Zepbound and Mounjaro). These medications are prescribed by licensed healthcare providers after a medical evaluation.

FDA-approved medications (like Wegovy, Zepbound) have undergone full clinical trials for safety and efficacy. Compounded versions contain the same active ingredients but are prepared by licensed compounding pharmacies based on individual prescriptions. Compounded formulations are not FDA-approved as finished products and have not undergone the same premarket review. They are typically more affordable. Your healthcare provider can help you understand which option is most appropriate for your situation.

Most programs follow a similar process: you complete an online health questionnaire, a licensed provider reviews your medical history and assesses eligibility, and if approved, a personalized treatment plan is created. Consultations may be conducted via video call, phone, or asynchronous review depending on the platform and state regulations. Approved medications are shipped directly to your home.

Generally, GLP-1 medications for weight management are considered for adults (18+) with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition such as hypertension, high cholesterol, or type 2 diabetes. Eligibility is ultimately determined by a licensed healthcare provider who reviews your individual medical history and circumstances.

The most commonly reported side effects include nausea, vomiting, diarrhea, constipation, and stomach pain — especially during the initial dosing period. These often diminish as your body adjusts to the medication. More serious side effects are less common but can include pancreatitis and gallbladder issues. Your prescribing provider should discuss all potential risks and monitor your progress throughout treatment.

Each provider is evaluated on a 10-point scale across six criteria: medication options (variety of formulations available), provider access (consultation quality and availability), pricing transparency (clarity of cost structure), support and monitoring (ongoing care and follow-up), convenience (ease of enrollment and use), and program breadth (services beyond basic prescriptions). Scores reflect publicly available service features and our editorial assessment.